Introduction. Family Planning and Pregnancy Management in Patients With Chronic Inflammatory Rheumatic Diseases.

Slides:

Advertisements

Similar presentations

Measuring Quality of Care in People with Arthritis Sarah Sampsel, MPH National Committee for Quality Assurance AcademyHealth 2004 ©2004 by the National.

Advertisements

PROTOCOL 588: OVERALL ASSESSMENT Concept is sound, well supported Vector is safe Transgene product is reasonably safe Overall, a phase I study seems acceptable.

Disease modified Anti-rheumatic drugs ( DMARD)

Monitoring Process for Pregnancy Category D or X Medications in Women of Childbearing Age Jody L. Lounsbery, PharmD, BCPS, Barbara Leone, MD University.

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs Daniel H. Solomon, MD, MPH,

Rheumatoid Arthritis Hayley Evans, CMCBI, King’s College London, UK

Anti-rheumatic Drugs In Pregnancy And Breastfeeding

The Nurse’s Role in Inflammatory Bowel Disease

Addressing the Challenges in Primary and Secondary Stroke Prevention

New Psoriasis Treatments

IL-12 and IL-23.

RISK RECOGNITION IN HEALTHCARE SETTINGS

Medication Effects That May Impair Driving Ability

Gout Management.

Optimizing Therapy for Osteoarthritis

Tailoring Statin Therapy in Women

Expert Perspectives on Clinically Challenging Cases in Narcolepsy

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Assessing and Modifying Risks for Older Drivers

Disclaimer. LEGAL AND POLICY CONSIDERATIONS OF NALOXONE FOR OPIOID TOXICITY REVERSAL.

Addressing Neuropsychiatric Symptoms in Patients With Dementia

Patient-Centered Care in Cystic Fibrosis

Case Challenges in Chronic Migraine

How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients

Management Considerations in Epilepsy Among Long-Term Care Residents

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Complicated Cases in Ulcerative Colitis

Obesity Management Today:

Blood pressure control: dependence on adherence

HBV Infection: Some Sobering Facts

What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data

Precision Management of RA and Comorbidities

Environmental Services and Infection Prevention

Clinical Updates in RA: New Developments and Insights From Washington

Improving Management of Type 2 Diabetes in Hispanic/Latino Patients

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Seizures in the Elderly: Treatment and Special Considerations

Contemporary Issues in Psoriasis Care: A Call to Action

Is RA Treatment Addressing the Real Needs of Patients?

Charting Progress in MS Treatment:

Poor Response to Initial Therapy for Migraine

Biotherapeutics.

Improving Therapeutic Management of Huntington's Disease in Long-Term Care.

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.

An Interprofessional Perspective on the Safe and Appropriate Use of Opioid Analgesics.

Management of Systematic Lupus Erythematosus

Treatment-Resistant Schizophrenia

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Managing Age-Related Clinical Issues in Hemophilia

Considerations in Managing Seizures in Women

Severe Asthma and Comorbidities

Insulin in Diabetes Management: Effective Patient Selection Is Key

THE TRUTH ABOUT MODERN OBESITY AGENTS: ARE THEY REALLY SAFE AND EFFECTIVE?

Critical Decision Points in Insomnia

Figure 1 Reproductive health in patients with rheumatic diseases

Issues in Patients With Severe Epilepsy

A Primer on Biosimilars

Case Studies in Peanut Allergy Immunotherapy

Low-dose glucocorticoid chronotherapy in rheumatoid arthritis (RA) include the night-time-release prednisone, a timing drug release formulation with administration.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Successful AF Ablation Outcomes

Classification Criteria for axSpA

Treatment Advances for RA

The Real Burden of Rosacea

Status of tapering in the first year of follow-up.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

Family Planning and Pregnancy Management in Patients With Chronic Inflammatory Rheumatic Diseases

Introduction

Key Issues for Women of Childbearing Age With CRDs

What Are the Barriers to Family Planning and Pregnancy in Patients of Childbearing Age?

Is Family Planning a Matter of Concern to Patients With CRD?

Are Patient Concerns Adequately Addressed by HCPs?

Family Planning: Timeline

Key Questions Before and During Pregnancy in Rheumatic Diseases

Key Questions Before and During Pregnancy in Rheumatic Diseases (cont)

Risk of Pregnancy Complications in Women With Inflammatory Arthritis

Methotrexate and Pregnancy

Overarching Principles for Use of Antirheumatic Drugs Before and During Pregnancy

Activity of Inflammatory Arthritis During Pregnancy

Drugs During Pregnancy Principal Considerations

Alternative Medications

Overarching Principles for Use of Antirheumatic Drugs Before and During Pregnancy (cont)

Consensus on Use of Biologic Drugs

NSAIDs and Pregnancy

Overarching Principles for Use of Antirheumatic Drugs Before and During Pregnancy (cont)

Consensus on Use of Biologic Drugs (cont)

Take-Home Messages

Abbreviations